KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Interest Expenses (2018 - 2020)

Xenon Pharmaceuticals (XENE) has disclosed Interest Expenses for 4 consecutive years, with $154000.0 as the latest value for Q2 2020.

  • On a quarterly basis, Interest Expenses fell 57.81% to $154000.0 in Q2 2020 year-over-year; TTM through Mar 2021 was $154000.0, a 85.23% decrease, with the full-year FY2020 number at $484000.0, down 66.25% from a year prior.
  • Interest Expenses was $154000.0 for Q2 2020 at Xenon Pharmaceuticals, down from $330000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $678000.0 in Q3 2018 to a low of $154000.0 in Q2 2020.
  • A 3-year average of $341714.3 and a median of $348000.0 in 2019 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 125.16% in 2019, then tumbled 57.81% in 2020.
  • Xenon Pharmaceuticals' Interest Expenses stood at $678000.0 in 2018, then tumbled by 48.67% to $348000.0 in 2019, then plummeted by 55.75% to $154000.0 in 2020.
  • Per Business Quant, the three most recent readings for XENE's Interest Expenses are $154000.0 (Q2 2020), $330000.0 (Q1 2020), and $348000.0 (Q4 2019).